New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2012
16:19 EDTJPM, JNJ, RMBS, LCC, AAMRQ, CASY, REGNOn The Fly: Closing Wrap
Stocks on Wall Street were lower following disappointing U.S. economic data. Stock futures were lower in premarket trading but tumbled following disappointing retail sales figures for the month of May. The market opened lower but soon found a level from where it started to build. The averages crossed into positive territory could not gain any upside momentum. The middle of the day was characterized by the market drifting back and forth across the baseline as it underwent a period of consolidation, in contrast to the previous two days, which were marked by big swings in the averages. In the last hour of trading the market fell sharply to wind up down for the day… ECONOMIC EVENTS: In the U.S., retail sales slipped 0.2%, which was in line with expectations, but if auto and gasoline data are excluded the "core" reading showed a decline of 0.1%, versus expectations of an increase of 0.4%. Producer prices in the month of May declined 1.0%, versus expectations of a decline of 0.6%, but if food and energy are removed the reading was up 0.2%, which was in line with forecasts. Business inventories grew 0.4% in April, versus expectations for an increase of 0.3%. In Europe, Italy’s national borrowing rate skyrocketed to its highest level since December, as investors became jittery about contagion from Spain’s request for external assistance… COMPANY NEWS: JPMorgan's (JPM) CEO Jamie Dimon testified in front of the Senate Banking Committee, saying that he expects the current quarter to be "solidly profitable" in spite of the "London Whale's" losses and that clawbacks of executive pay are likely following the bank's review of the incident. Dimon argued that complex institutions are necessary to meet the needs of business and that there are many advantages and only some negatives to big banks. Following his testimony JPMorgan’s shares rose 53c, or 1.57%, to $34.30... Johnson & Johnson (JNJ) shares rose $1.37, or 2.17%, to $64.45, after JPMorgan, Jefferies and Raymond James all upgraded the stock this morning. Last night, the pharmaceutical giant confirmed it has received U.S. regulatory clearance for its proposed acquisition of Synthes and announced a new accelerated share repurchase agreement... MAJOR MOVERS: Among the notable gainers were Rambus (RMBS), up 44c, or 9.16%, to $5.30, after being initiated with a Buy rating and $10 price target at Sidoti, and U.S. Airways (LCC), up 54c, or 4.72%, to $11.97, after multiple sources indicated that the company plans to file paperwork with U.S. antitrust regulators as soon as next month for a proposed merger with AMR (AAMRQ). Noteworthy losers included Casey’s General Stores (CASY), down $7.73, or 12.90%, to $52.18, after missing on Q4 EPS, and Regeneron (REGN), down $15.97, or 12.49%, to $111.88, after competitor Ophthotech announced positive data from a clinical trial… INDICES: The Dow lost 77.42, or 0.62%, to 12,496.38; the Nasdaq fell 24.46, or 0.86%, to 2,818.61; and the S&P 500 dropped 9.30, or 0.70%, to 1,314.88.
News For JPM;JNJ;RMBS;LCC;AAMRQ;CASY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 20, 2014
16:10 EDTRMBSRambus expects Q4 revenue $70M-$75M, consensus $74.38M
Subscribe for More Information
16:09 EDTRMBSRambus reports Q3 EPS 13c, consensus 5c
Subscribe for More Information
15:30 EDTRMBSNotable companies reporting after market close
Subscribe for More Information
12:36 EDTJNJOptions with decreasing implied volatility
Subscribe for More Information
09:31 EDTJPMRobinhood.org to hold conference
Subscribe for More Information
08:14 EDTJNJPharmacyclics files supplmeental NDA for Imbruvica for macroglobulinemia
Pharmacyclics (PCYC) announced that it has submitted a supplemental New Drug Application to the FDA based on data from a Phase 2 study evaluating the use of IMBRUVICA in patients with Waldenstrom's macroglobulinemia. IMBRUVICA, which received FDA Breakthrough Therapy Designation in February 2013 for patients with WM, is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
07:21 EDTJPMFederal Reserve Bank of New York and Boston to hold a workshop
Subscribe for More Information
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
16:55 EDTJNJ, JPMStocks end volatile week lower amid oil price plunge
Subscribe for More Information
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
09:32 EDTRMBSRambus upgraded to Buy from Neutral at Sidoti
Subscribe for More Information
09:06 EDTJPMJPMorgan and PNC Financial weakness a buying opportunity, say Morgan Stanley
Subscribe for More Information
09:06 EDTREGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
07:00 EDTJPMJPMorgan in talks to build corporate campus in Manhattan, NY Times reports
JPMorgan Chase (JPM) is in negotiations with New York state and city officials over a potential $6.5B deal that would result in the construction of a corporate campus with two high rises on the West Side of Manhattan, the Wall Street Journal reports. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use